“We give companies patent monopolies that allow them to sell drugs at mark-ups of several thousand percent above their production costs. How can we be surprised when they lie or conceal information to push their drugs as widely as possible?”
The price-gouging bill was passed by the Democrat-led General Assembly with near unanimous support this year and only governs off-patent and generic drugs, not branded medications protected by patent laws.
BALTIMORE — A trade group for generic drugmakers brought a federal complaint Thursday to block Maryland’s attempt of a crackdown on pharmaceutical price gouging. Set to take effect in October without the signature of Republican Gov. Larry
The case hinged on a little-known aspect of the Affordable Care Act that would expedite the release of generic drugs, a provision contested by major pharmaceuticals firms.
The Supreme Court dealt a blow to big pharma on Monday, ruling that companies making generic “biosimilars” to brand-name drugs don’t have to wait an extra six months after gaining federal approval before selling their drugs. The ruling, written by Justice Clarence
The suit is part of an ongoing, two-year long antitrust investigation conducted by the U.S. Department of Justice.
A lawsuit filed Thursday in the U.S. District Court for the District of Connecticut alleges Heritage Pharmaceuticals, EpiPen-maker Mylan NV, and others conspired to manipulate U.S. drug prices. The suit was filed on behalf of the states of Connecticut, Delaware,
The company will no longer hire doctors to promote its drugs and will stop tying drug rep pay to number of prescriptions written.
In a major departure from industry practice, GlaxoSmithKline, the sixth-largest global drug maker, announced Tuesday that it will no longer hire doctors to promote its drugs. The company also will stop tying
Last week the FDA approved studies of CBD, a cannabis-based drug.
In order to reap the health benefits of marijuana without getting the “high” from the plant’s psychoactive ingredient, many medical marijuana patients have turned to a variety of the plant that is so low in THC that it is nearly impossible to get high. Instead, the plant is high in another ingredient -- cannabidiol, or CBD, which has been
Increased regulation could bring an end to small compounding pharmacies in the era of Big Pharma.
After a deadly meningitis outbreak traced to a New England compounding pharmacy killed at least 50 Americans last year, the U.S. government is poised to step in and increase regulation of these niche facilities through the Food and Drug Administration (FDA).
